128 related articles for article (PubMed ID: 22564760)
1. Research chemicals marketed as legal highs: the case of pipradrol derivatives.
Coppola M; Mondola R
Toxicol Lett; 2012 Jul; 212(1):57-60. PubMed ID: 22564760
[TBL] [Abstract][Full Text] [Related]
2. Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as "bath salts" or "plant food".
Coppola M; Mondola R
Toxicol Lett; 2012 Jun; 211(2):144-9. PubMed ID: 22459606
[TBL] [Abstract][Full Text] [Related]
3. Use and acute toxicity associated with the novel psychoactive substances diphenylprolinol (D2PM) and desoxypipradrol (2-DPMP).
Wood DM; Dargan PI
Clin Toxicol (Phila); 2012 Sep; 50(8):727-32. PubMed ID: 22882169
[TBL] [Abstract][Full Text] [Related]
4. Aminoindanes--the next wave of 'legal highs'?
Sainsbury PD; Kicman AT; Archer RP; King LA; Braithwaite RA
Drug Test Anal; 2011; 3(7-8):479-82. PubMed ID: 21748859
[TBL] [Abstract][Full Text] [Related]
5. "Legal Highs"--An Emerging Epidemic of Novel Psychoactive Substances.
Zawilska JB
Int Rev Neurobiol; 2015; 120():273-300. PubMed ID: 26070762
[TBL] [Abstract][Full Text] [Related]
6. 2-DPMP (desoxypipradrol, 2-benzhydrylpiperidine, 2-phenylmethylpiperidine) and D2PM (diphenyl-2-pyrrolidin-2-yl-methanol, diphenylprolinol): A preliminary review.
Corkery JM; Elliott S; Schifano F; Corazza O; Ghodse AH
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):253-8. PubMed ID: 22687464
[TBL] [Abstract][Full Text] [Related]
7. 5-Iodo-2-aminoindan (5-IAI): chemistry, pharmacology, and toxicology of a research chemical producing MDMA-like effects.
Coppola M; Mondola R
Toxicol Lett; 2013 Mar; 218(1):24-9. PubMed ID: 23347877
[TBL] [Abstract][Full Text] [Related]
8. [Synthetic drugs: the new low-cost landscape of drugs].
Karila L; Petit A; Cottencin O; Coscas S; Reynaud M
Rev Prat; 2012 May; 62(5):664-6. PubMed ID: 22730798
[TBL] [Abstract][Full Text] [Related]
9. The Changing Drug Culture: Emerging Drugs of Abuse and Legal Highs.
Albertson TE; Chenoweth JA; Colby DK; Sutter ME
FP Essent; 2016 Feb; 441():18-24. PubMed ID: 26881769
[TBL] [Abstract][Full Text] [Related]
10. Analysis of first and second generation legal highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid chromatography and time of flight mass spectrometry.
Shanks KG; Dahn T; Behonick G; Terrell A
J Anal Toxicol; 2012 Jul; 36(6):360-71. PubMed ID: 22586208
[TBL] [Abstract][Full Text] [Related]
11. Clinical toxicology of newer recreational drugs.
Hill SL; Thomas SH
Clin Toxicol (Phila); 2011 Oct; 49(8):705-19. PubMed ID: 21970769
[TBL] [Abstract][Full Text] [Related]
12. Designer drugs: a medicinal chemistry perspective.
Carroll FI; Lewin AH; Mascarella SW; Seltzman HH; Reddy PA
Ann N Y Acad Sci; 2012 Feb; 1248():18-38. PubMed ID: 22092008
[TBL] [Abstract][Full Text] [Related]
13. 4-methylamphetamine (4-MA): chemistry, pharmacology and toxicology of a new potential recreational drug.
Coppola M; Mondola R
Mini Rev Med Chem; 2013 Dec; 13(14):2097-101. PubMed ID: 24195663
[TBL] [Abstract][Full Text] [Related]
14. New drugs of abuse in North America.
Haroz R; Greenberg MI
Clin Lab Med; 2006 Mar; 26(1):147-64, ix. PubMed ID: 16567229
[TBL] [Abstract][Full Text] [Related]
15. Exploring the Attractiveness of New Psychoactive Substances (NPS) among Experienced Drug Users.
van Amsterdam JG; Nabben T; Keiman D; Haanschoten G; Korf D
J Psychoactive Drugs; 2015; 47(3):177-81. PubMed ID: 26098724
[TBL] [Abstract][Full Text] [Related]
16. Designer Drug (DD) abuse in Poland; a review of the psychoactive and toxic properties of substances found from seizures of illegal drug products and the legal consequences thereof. Part II--piperazines/piperidines, phenylethylamines, tryptamines and miscellaneous 'others'.
Biliński P; Hołownia P; Kapka-Skrzypczak L; Wojtyła A
Ann Agric Environ Med; 2012; 19(4):871-82. PubMed ID: 23311821
[TBL] [Abstract][Full Text] [Related]
17. Emerging drugs of abuse: clinical and legal considerations.
Aoun EG; Christopher PP; Ingraham JW
R I Med J (2013); 2014 Jun; 97(6):41-5. PubMed ID: 24905374
[TBL] [Abstract][Full Text] [Related]
18. Detection and quantification of new designer drugs in human blood: Part 2 - Designer cathinones.
Ammann D; McLaren JM; Gerostamoulos D; Beyer J
J Anal Toxicol; 2012 Jul; 36(6):381-9. PubMed ID: 22593565
[TBL] [Abstract][Full Text] [Related]
19. Electrochemical oxidation of amphetamine-like drugs and application to electroanalysis of ecstasy in human serum.
Garrido EM; Garrido JM; Milhazes N; Borges F; Oliveira-Brett AM
Bioelectrochemistry; 2010 Aug; 79(1):77-83. PubMed ID: 20051327
[TBL] [Abstract][Full Text] [Related]
20. 'Ivory wave' toxicity in recreational drug users; integration of clinical and poisons information services to manage legal high poisoning.
Murray DB; Potts S; Haxton C; Jackson G; Sandilands EA; Ramsey J; Puchnarewicz M; Holt DW; Johnston A; Nicholas Bateman D; Dear JW
Clin Toxicol (Phila); 2012 Feb; 50(2):108-13. PubMed ID: 22224933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
